Results 111 to 120 of about 11,950 (166)
Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System. [PDF]
J Clin MedSridharan K, Sivaramakrishnan G.
europepmc +1 more source
Editorial: Advancements in translational stroke research: spotlight on the blood-brain barrier. [PDF]
Front PharmacolChen H, Iweka CA, Yang Y, Hermann DM.
europepmc +1 more source
Antiplatelet therapy trends in Chinese ischemic stroke patients 2019-2024. [PDF]
Sci RepWu M, Jiang H, Sun A, Zhu B, Zhao Z.
europepmc +1 more source
Dual antiplatelet therapy use after non-cardioembolic ischemic stroke or transient ischemic attack: a meta-analysis of trials and cohort studies. [PDF]
Front NeurolHlupeni A +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinical Pharmacology and Therapeutics, 1982
The kinetics of the antiplatelet drug dipyridamole were studied in six normal subjects (three men and three women) who were ages 22 to 34 yr old. Each received 20 mg IV and four also took a 50-mg oral dose. Blood samples were collected after each dose for a period of 3 days and concentrations of dipyridamole were measured by a sensitive and specific ...
C, Mahony +3 more
openaire +2 more sources
The kinetics of the antiplatelet drug dipyridamole were studied in six normal subjects (three men and three women) who were ages 22 to 34 yr old. Each received 20 mg IV and four also took a 50-mg oral dose. Blood samples were collected after each dose for a period of 3 days and concentrations of dipyridamole were measured by a sensitive and specific ...
C, Mahony +3 more
openaire +2 more sources
Pharmacokinetics of Dipyridamole
Acta Pharmacologica et Toxicologica, 1979AbstractDipyridamole, though originally introduced as a coronary vasodilator, has lately been increasingly investigated in the treatment of thromboembolic diseases because of its inhibitory influence upon blood platelet function. The compound is eliminated from the organism by hepatic biotransformation to the monoglucuronide, which almost exclusively ...
F, Nielsen-Kudsk, A K, Pedersen
openaire +2 more sources
Echocardiography, 1992
Intravenous dipyridamole is a potent coronary vasodilator that has been extensively investigated over the past several years in the noninvasive assessment of patients with suspected coronary artery disease when exercise cannot be performed or is suboptimal.
R, Castello, A J, Labovitz
openaire +2 more sources
Intravenous dipyridamole is a potent coronary vasodilator that has been extensively investigated over the past several years in the noninvasive assessment of patients with suspected coronary artery disease when exercise cannot be performed or is suboptimal.
R, Castello, A J, Labovitz
openaire +2 more sources
Dipyridamole in the Nephritides
American Journal of Therapeutics, 1998A summary is given of the properties of dipyridamole and of the trials at the time this article was written that indicate its potential efficacy in the therapy of glomerulonephritides.
openaire +2 more sources